Literature DB >> 9630047

Multiple combined therapy for severe Henoch-Schönlein nephritis in children.

K Iijima1, S Ito-Kariya, H Nakamura, N Yoshikawa.   

Abstract

From 1980 through 1992, 14 children with Henoch-Schönlein nephritis (HSN) showing severe glomerular changes (grade IV or V) were given a multiple combined therapy with prednisolone, cyclophosphamide, heparin/warfarin, and dipyridamole, and were followed for 7.5+/-0.9 years. The period between the onset of nephritis and the start of therapy was 0.8+/-0.4 years. Ten patients underwent follow-up biopsy after therapy. The percentage of glomeruli having crescents/segmental lesions was significantly reduced after therapy (70%+/-5% vs. 42%+/-7%, P <0.01), due mainly to the resolution of crescents (51%+/-8% vs. 13%+/-5%, P <0.01). Thus, histological grade was significantly improved (5 grade IV and 5 grade V vs. 7 grade III and 3 grade IV, P <0.01). After an average follow-up period of 7.5 years, 9 patients showed normal urine and renal function, 4 showed minor urinary abnormalities, and 1 heavy proteinuria. No patient developed chronic renal insufficiency. These findings suggest that the multiple combined therapy could be effective. for histologically severe HSN, although a prospective controlled study should be performed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9630047     DOI: 10.1007/s004670050447

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  36 in total

Review 1.  Henoch-Schönlein purpura.

Authors:  E J Tizard
Journal:  Arch Dis Child       Date:  1999-04       Impact factor: 3.791

2.  Early treatment with oral immunosuppressants in severe proteinuric purpura nephritis.

Authors:  Salvatore Li Volti; Giovanni Li Volti
Journal:  Pediatr Nephrol       Date:  2003-09-12       Impact factor: 3.714

Review 3.  Adjuvant treatments for Henoch-Schönlein purpura nephritis in children: A systematic review.

Authors:  Marco Zaffanello; Milena Brugnara; Massimo Franchini; Vassilios Fanos
Journal:  Curr Ther Res Clin Exp       Date:  2009-06

4.  [17 year old patient with acute abdominal pain, hematochezia and exanthema].

Authors:  D Dürr; R Baia; R Maurer; S Lautenschlager; A Schnider; M Fliegner
Journal:  Internist (Berl)       Date:  2005-06       Impact factor: 0.743

Review 5.  Treatment-based literature of Henoch-Schönlein purpura nephritis in childhood.

Authors:  Marco Zaffanello; Vassilios Fanos
Journal:  Pediatr Nephrol       Date:  2008-12-09       Impact factor: 3.714

6.  Pitfalls in recommending evidence-based guidelines for a protean disease like Henoch-Schönlein purpura nephritis.

Authors:  Jean-Claude Davin; Rosanna Coppo
Journal:  Pediatr Nephrol       Date:  2013-07-09       Impact factor: 3.714

7.  Value of the Oxford classification of IgA nephropathy in children with Henoch-Schönlein purpura nephritis.

Authors:  Ke Xu; Lili Zhang; Jie Ding; Suxia Wang; Baige Su; Huijie Xiao; Fang Wang; Xuhui Zhong; Yanming Li
Journal:  J Nephrol       Date:  2017-11-28       Impact factor: 3.902

8.  A clinicopathological comparison between IgA nephropathy and Henoch-Schönlein purpura nephritis in children: use of the Oxford classification.

Authors:  Xueqian Li; Mengmeng Tang; Xingfeng Yao; Nan Zhang; Jianfeng Fan; Nan Zhou; Qiang Sun; Zhi Chen; Qun Meng; Lei Lei; Hejia Zhang; Chen Ling; Lin Hua; Xiangmei Chen; Xiaorong Liu
Journal:  Clin Exp Nephrol       Date:  2019-08-29       Impact factor: 2.801

9.  Improved outcome of Henoch-Schonlein purpura nephritis by early intensive treatment.

Authors:  Fang Deng; Ling Lu; Qin Zhang; Bo Hu; Xun Xia
Journal:  Indian J Pediatr       Date:  2011-07-08       Impact factor: 1.967

10.  Resolution of Henoch-Schönlein purpura nephritis after acquired IgA deficiency.

Authors:  Mototsugu Tanaka; George Seki; Kenichi Ishizawa; Junichi Hirahashi; Kenichiro Miura; Takashi Sekine; Tomonosuke Someya; Hiroshi Hataya; Michio Nagata; Toshiro Fujita
Journal:  Pediatr Nephrol       Date:  2010-06-06       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.